Generic Medicine Info
Indications and Dosage
Psoriasis vulgaris
Adult: As 4 mcg/g lotion or ointment: Apply sparingly onto affected areas once daily, preferably at bedtime. Max: 10 g of ointment or 10 mL of lotion daily; 280 mcg weekly (e.g. 30 mL lotion + 40 g ointment). Treatment duration depends on severity of lesions; may be used continuously or intermittently for up to 8 weeks (lotion), or up to 18 months (ointment).
Hypersensitivity. Severe cardiac disease, hypercalcaemia, Ca metabolism disorders, psoriasis punctata or psoriasis pustulosa. Severe renal and hepatic impairment.
Special Precautions
Combined treatment with UV radiation. Elderly. Pregnancy and lactation.
Adverse Reactions
Significant: Hypercalcaemia.
Immune system disorders: Hypersensitivity reactions including swelling, oedema, face oedema.
Skin and subcutaneous tissue disorders: Itching, rash (erythematous, macular, papular, vesicular), skin irritation (e.g. burning, erythema), worsening of psoriasis.
Patient Counseling Information
Avoid contact with eyes. Do not smoke or go near naked flames.
Monitoring Parameters
Monitor Ca (serum and corrected levels), albumin; vitamin D (in patients receiving vitamin D therapy); renal function (as clinically indicated).
Drug Interactions
Increased efficacy and shortened period of UVB radiation. May enhance toxic effects of other vitamin D analogues. Increased hypercalcaemic effect with thiazide and thiazide-like diuretics.
Mechanism of Action: Tacalcitol, a vitamin D3 derivative, binds to keratinocyte vitamin D3 receptor, thus inhibiting keratinocyte hyperproliferation and inducing differentiation of these cells.
Absorption: <0.5% absorbed through psoriatic skin.
Distribution: Plasma protein binding: Completely bound, mainly to vitamin D binding protein.
Metabolism: Metabolised to 1-α, 24, 25 (OH)3 vitamin D3 (primary).
Excretion: Via urine.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 5283734, Tacalcitol. https://pubchem.ncbi.nlm.nih.gov/compound/Tacalcitol. Accessed Nov. 21, 2023.

Store below 25°C.
MIMS Class
Psoriasis, Seborrhea & Ichthyosis Preparations
ATC Classification
D05AX04 - tacalcitol ; Belongs to the class of other antipsoriatics for topical use.
Anon. Tacalcitol. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 18/09/2023.

Buckingham R (ed). Tacalcitol. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 18/09/2023.

Curatoderm 4 mcg/g Ointment (Almirall Hermal GmbH). MHRA. https://products.mhra.gov.uk. Accessed 18/09/2023.

Curatoderm 4 micrograms/g Lotion (Almirall Hermal GmbH). MHRA. https://products.mhra.gov.uk. Accessed 18/09/2023.

Joint Formulary Committee. Tacalcitol. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 18/09/2023.

Disclaimer: This information is independently developed by MIMS based on Tacalcitol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in